Bernstein: Gilead’s HIV business drives an earnings beat as 2028 pricing pressure is quantified
Third-quarter revenue and earnings per share exceeded market consensus by 6% and 15%, respectively. The company raised its full-year sales guidance and expects a Biktarvy price reduction to lower 2028 revenue by approximately 1.5 billion dollars; growth from new medicines and pipeline diversification are key to offsetting the pressure.